Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives

Etienne Crickx; Jean-Claude Weill; Claude-Agnès Reynaud; Matthieu Mahévas

doi:10.1016/j.kint.2019.12.025

Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives

Kidney Int. 2020 May;97(5):885-893. doi: 10.1016/j.kint.2019.12.025. Epub 2020 Jan 30.

Authors

Etienne Crickx¹, Jean-Claude Weill², Claude-Agnès Reynaud², Matthieu Mahévas³

Affiliations

¹ Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médicale U1151/Centre National de la Recherche Scientifique UMS 8253, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-immunes de L'adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France.
² Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médicale U1151/Centre National de la Recherche Scientifique UMS 8253, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
³ Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médicale U1151/Centre National de la Recherche Scientifique UMS 8253, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-immunes de L'adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France. Electronic address: matthieu.mahevas@aphp.fr.

PMID: 32229095
DOI: 10.1016/j.kint.2019.12.025

Abstract

B-cell depletion with anti-CD20 monoclonal antibodies is widely used for the treatment of autoimmune diseases. This review will discuss mechanisms contributing to success or failure of B-cell depletion therapy in antibody-mediated autoimmune diseases. It will also explain how key information about disease pathogeny can be provided by the different outcomes observed after B-cell depletion therapy. These findings provide the basis for future innovative therapeutic strategies aiming at an optimized B cell and/or plasma cell depletion to increase long-term disease remission.

Keywords: cell survival; systemic lupus erythematosus; vasculitis.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antigens, CD20
Autoimmune Diseases* / therapy
B-Lymphocytes
Humans
Lupus Erythematosus, Systemic*
Lymphocyte Depletion
Rituximab / therapeutic use

Substances

Antibodies, Monoclonal
Antigens, CD20
Rituximab